Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2015

Open Access 01-10-2015 | Review

Safety and Toxicology of Cannabinoids

Authors: Jane Sachs, Erin McGlade, Deborah Yurgelun-Todd

Published in: Neurotherapeutics | Issue 4/2015

Login to get access

Abstract

There is extensive research on the safety, toxicology, potency, and therapeutic potential of cannabis. However, uncertainty remains facilitating continued debate on medical and recreational cannabis policies at the state and federal levels. This review will include a brief description of cannabinoids and the endocannabinoid system; a summary of the acute and long-term effects of cannabis; and a discussion of the therapeutic potential of cannabis. The conclusions about safety and efficacy will then be compared with the current social and political climate to suggest future policy directions and general guidelines.
Appendix
Available only for authorised users
Literature
1.
UNODC. World Drug Report 2013. United Nations Publication Vienna, 2013.
2.
Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2013 National Survey on Drug Use and Health: Summary of national findings. Substance Abuse and Mental Health Servicels Administration, Rockville, MD, 2014.
3.
Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539-548.PubMedCrossRef
4.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacother 2013;33:195-209.CrossRef
5.
McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2015;172:737-753.PubMedPubMedCentralCrossRef
6.
Benbadis SR, Sanchez-Ramos J, Bozorg A, et al. Medical marijuana in neurology. Exp Rev Neurother 2014;14:1453-1465.CrossRef
7.
8.
Pertwee R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.PubMedCentralPubMedCrossRef
9.
10.
11.
12.
Suarez-Pinilla P, Lopez-Gil J, Crespo-Facorro B. Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun 2014;40:269-282.PubMedCrossRef
13.
Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Crippa AS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6:237-249.CrossRef
14.
15.
16.
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996;91:1585-11614.PubMedCrossRef
17.
Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012;5:32-40.PubMedCrossRef
18.
Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med 2013;28:8-12.PubMedCrossRef
19.
McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008;103:1100-1109.PubMedCrossRef
20.
Repp K, Raich A. Marijuana and health: a comprehensive review of 20 years of research. Washington County Oregon: Department of Health and Human Services; 2014.
21.
Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 2005;(168):719-786.PubMedCrossRef
22.
Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 1991;40:671-676.PubMedCrossRef
23.
Wall ME, Sadler BM, Brine D, Taylor H, Perez‐Reyes M. Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-363.PubMedCrossRef
24.
25.
Zuurman L, Passier P, de Kam M, Kleijn H, Cohen A, van Gerven J. Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 2009;23:633-644.PubMedCrossRef
26.
Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007;4:1744-1769.PubMedCrossRef
27.
Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy 2009;20:458-466.PubMedCrossRef
28.
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-1391.PubMedCrossRef
29.
30.
Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014;113:187-190.PubMedCrossRef
31.
Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician 2014;60:1083-1090.PubMedCentralPubMed
32.
33.
34.
Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;370:2219-2227.PubMedCrossRef
35.
Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:849-863.PubMedCrossRef
36.
Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005;35:265-275.PubMedCrossRef
37.
Maertens RM, White PA, Williams A, Yauk CL. A global toxicogenomic analysis investigating the mechanistic differences between tobacco and marijuana smoke condensates in vitro. Toxicology 2013;308:60-73.PubMedCrossRef
38.
Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev 2014;18:477-487.PubMedCrossRef
39.
Tramèr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16.PubMedCentralPubMedCrossRef
40.
Yamamoto I, Watanabe K, Matsunaga T, Kimura T, Funahashi T, Yoshimura H. Pharmacology and toxicology of major constituents of marijuana—on the metabolic activation of cannabinoids and its mechanism. Toxin Rev 2003;22:577-589.CrossRef
41.
42.
Lynch ME, Campbell F. Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735-744.PubMedCentralPubMedCrossRef
43.
Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014;34:587-591.PubMedCrossRef
44.
Kobayashi H, Suzuki T, Kamata R, et al. Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. J Toxicol Sci 1999;24:1-16.PubMedCrossRef
45.
Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 2013;23:117-137.PubMedCentralPubMedCrossRef
46.
Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 2012;109:E2657-E2664.PubMedCentralPubMedCrossRef
47.
Schoeler T, Bhattacharyya S. The effect of cannabis use on memory function: an update. Subst Abuse Rehabil 2013;4:11-27.PubMedCentralPubMed
48.
Ehrler M, McGlade EC, Yurgelun-Todd D. Subjective and cognitive effects of cannabinoids in marijuana smokers. In: Campolongo P, Fattore L, editors. Cannabinoid modulation of emotion, memory, and motivation. New York: Springer; 2015. p. 159–181.
49.
50.
Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5:1.PubMedCentralPubMedCrossRef
51.
Gonzalez R, Carey C, Grant I. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review. J Clin Pharmacol 2002;42(Suppl.1):48S-57S.PubMedCrossRef
52.
Solowij N, Pesa N. Cognitive abnormalities and cannabis use. Rev Bras Psiquiatr 2010;32:531-540.CrossRef
53.
Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun‐Todd D. Cognitive Measures in long‐term cannabis users. J Clin Pharmacol 2002;42(Suppl. 1):41S-47S.PubMedCrossRef
54.
Pope Jr HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep 2001;3:507-512.PubMedCrossRef
55.
Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003;9:679-689.PubMedCrossRef
56.
57.
James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res 2013;214:181-189.PubMedCrossRef
58.
Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003;69:303-310.PubMedCrossRef
59.
Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996;275:521-527.PubMedCrossRef
60.
Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PloS One 2013;8:e55821.PubMedCentralPubMedCrossRef
61.
Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M. Structural MRI findings in long-term cannabis users: what do we know? Substance Use Misuse 2010;45:1787-1808.PubMedCrossRef
62.
Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010;40:383-398.PubMedCrossRef
63.
Rapp C, Bugra H, Riecher-Rössler A, Tamagni C, Borgwardt S. Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des 2012;18:5070.PubMedCentralPubMedCrossRef
64.
Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 2011;220:164-172.PubMedCentralPubMedCrossRef
65.
McCormick MA, Shekhar A. Review of marijuana use in the adolescent population and implications of its legalization in the United States. J Drug Metab Toxicol 2014;5:2.
66.
Jacobus J, Squeglia LM, Meruelo AD, et al. Cortical thickness in adolescent marijuana and alcohol users: a three-year prospective study from adolescence to young adulthood. Dev Cog Neurosci 2015 Apr 27 [Epub ahead of print].
67.
Wetherill RR, Jagannathan K, Hager N, Childress AR, Rao H, Franklin TR. Cannabis, cigarettes, and their co-occurring use: disentangling differences in gray matter volume. Int J Neuropsychopharmacol 2015:pyv061.
68.
Gruber SA, Yurgelun-Todd DA. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Cog Brain Res 2005;23:107-118.CrossRef
69.
Churchwell JC, Yurgelun-Todd DA. Neuroimaging, adolescence, and risky behavior. In: MT B, DH F, R M (eds) Inhibitory control and drug abuse prevention. Springer, ??, 2011, pp. 101-122.
70.
Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacol 2004;176:239-247.CrossRef
71.
Chang L, Cloak C, Yakupov R, Ernst T. Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J Neuroimmune Pharmacol 2006;1:65-76.PubMedCrossRef
72.
Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychol 2007;61:1281-1289.CrossRef
73.
Prescot AP, Renshaw PF, Yurgelun-Todd DA. γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 2013;129:232-239.PubMedPubMedCentralCrossRef
74.
Crippa JAS, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25:121-130.PubMedCrossRef
75.
Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 2015;171:39-47.PubMedCrossRef
76.
Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2014;44:797-810.PubMedCrossRef
77.
Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009;24:515-523.PubMedCrossRef
78.
Nussbaum AM, Thurstone C, McGarry L, Walker B, Sabel AL. Use and diversion of medical marijuana among adults admitted to inpatient psychiatry. Am J Drug Alcohol Abuse 2015;41:166-172.PubMedCrossRef
79.
Ferretjans R, Moreira FA, Teixeira AL, Salgado JV. The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Rev Bras Psiquiatr 2012;34:163-193.CrossRef
80.
Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-194.PubMedCrossRef
81.
Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328.PubMedCrossRef
82.
Szoke A, Galliot AM, Richard JR, et al. Association between cannabis use and schizotypal dimensions—a meta-analysis of cross-sectional studies. Psychiatry Res 2014;219:58-66.PubMedCrossRef
83.
Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin 2013;263:3-13.CrossRef
84.
J van der Meer F, Velthorst E, J Meijer C, WJ Machielsen M, de Haan L. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des 2012;18:5036-5044.
85.
Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015;162:153-161.PubMedCrossRef
86.
Roser P, S Haussleiter I. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 2012;18:5141-5155.
87.
Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010;29:318-330.PubMedCrossRef
88.
Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE. Use of alcohol, cigarettes, and number of illicit drugs declines among U.S. teens. Ann Arbor, MI, 2014/ Retrieved 20 Apr. 2015. Report No.
89.
National Intstitute of Drug Abuse (NIDA). Research Report Series: Marijuana. 2015.
90.
Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 2000;22:325-336.PubMedCrossRef
91.
Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 2002;24:309-320.PubMedCrossRef
92.
de Moraes Barros MC, Guinsburg R, Mitsuhiro S, Chalem E, Laranjeira RR. Neurobehavioral profile of healthy full-term newborn infants of adolescent mothers. Early Hum Dev 2008;84:281-287.PubMedCrossRef
93.
Fried PA, Makin J. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol 1987;9:1-7.PubMedCrossRef
94.
Mincis M, Pfeferman A, Guimarães R, Ramos O, Zukerman E, Karniol I, et al. [Chronic administration of cannabidiol in man. Pilot study]. AMB Rev Assoc Med Bras 1973;19:185-190 (in Portuguese).PubMed
95.
Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556-1563.PubMedCentralPubMedCrossRef
96.
97.
98.
Wade DT, Makela P, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis 2006;12:639-645.PubMedCrossRef
99.
Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, O'Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS A psychometric and MRI study. Neurology 2014;82:1879-1887.PubMedCentralPubMedCrossRef
100.
Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurololgy 2011;76:1153-1160.CrossRef
101.
Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008;71:164-169.PubMedCrossRef
102.
Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012;6:CD009270.PubMed
103.
Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009;(2):CD007204.PubMed
104.
Solas M, Francis PT, Franco R, Ramirez MJ. CB 2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging 2013;34:805-808.PubMedCrossRef
105.
Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J Mol Med 2006;84:253-258.PubMedCrossRef
106.
Eubanks LM, Rogers CJ, Beuscher AE, IV, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006;3:773-777.PubMedCentralPubMedCrossRef
107.
Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.PubMedCrossRef
108.
Sagredo O, Ruth Pazos M, Valdeolivas S, Fernández-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat CNS Drug Discov 2012;7:41-48.PubMedCrossRef
109.
McLoughlin BC, Pushpa‐Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev 2014;10:CD004837.PubMed
110.
Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20:683-686.PubMedCrossRef
111.
Boychuk DG, Goddard G, Mauro G, Orellana MF. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. J Oral Facial Pain Headache 2015;29:7-14.PubMedCrossRef
112.
Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliat Care Pharmacother 2014;28:216-225.PubMedCrossRef
113.
Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10:1353-1368.PubMedCrossRef
114.
Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012;1:CD008921.PubMed
115.
Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH rapid response reports. CADTH, Ottawa, 2014.
116.
Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 2008;17:431-443.CrossRef
117.
118.
Mack A, Joy J. Marijuana as medicine?: the science beyond the controversy: National Academies Press, 2000.
119.
120.
Lopez-Pelayo H, Batalla A, Balcells MM, Colom J, Gual A. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med 2015;45:1121-1133.PubMedCrossRef
121.
Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2013.
122.
Okaneku J, Vearrier D, McKeever RG, LaSala GS, Greenberg MI. Change in perceived risk associated with marijuana use in the United States from 2002 to 2012. Clin Toxicol 2015;53:151-155.CrossRef
123.
Research PHL. Laws, maps & data: law atlas. Robert Wood Johnson Foundation.
124.
Pacula RL, Hunt P, Boustead A. Words can be deceiving: a review of variation among legally effective medical marijuana laws in the United States. J Drug Policy Anal 2014;7:1-19.PubMedCentralPubMedCrossRef
125.
Blumenson E, Nilsen E. No rational basis: the pragmatic case for marijuana law reform. Va J Soc Pol'y & L. 2009;17:43.
126.
127.
128.
Cohen PJ. Medical marijuana 2010: it's time to fix the regulatory vacuum. J Law Med Ethics 2010;38:654-666.PubMedCrossRef
129.
Caulkins JP, Hawken A, Kilmer B, Kleiman MA. Marijuana Legalization: what everyone needs to know. Oxford, Oxford University Press, 2012.
130.
Kilmer B. Policy designs for cannabis legalization: starting with the eight Ps. Am J Drug Alcohol Ab 2014;40:259-261.
131.
Caulkins JP, Hawken A, Kilmer B, Kleiman MA. High tax states: options for gleaning revenue from legal cannabis. Or L Rev 2012;91:1041.
Metadata
Title
Safety and Toxicology of Cannabinoids
Authors
Jane Sachs
Erin McGlade
Deborah Yurgelun-Todd
Publication date
01-10-2015
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2015
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0380-8

Other articles of this Issue 4/2015

Neurotherapeutics 4/2015 Go to the issue

Commentary

Parsing Physiological Functions of Erythropoietin One Domain at a Time

Original Article

A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection

Original Article

Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons

Review

An Overview of Products and Bias in Research

Editorial

Cannabinoids in the Treatment of Neurological Disorders

Review

Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics